SCHEMBL16534874

SCHEMBL16534874

CCc1c(C)[nH]c2c(-n3cnc(C(=O)NC)c3)cnn2c1=O

nearest known ligand 0.32

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.32
▸ PARP2 Q9UGN5 2/20 0.32
▸ PARP6 Q2NL67 1/20 0.32
▸ PARP3 Q9Y6F1 1/20 0.32
▸ BRD4 O60885 1/20 0.32
▸ BRPF1 P55201 1/20 0.32
▸ EP300 Q09472 1/20 0.32
▸ CREBBP Q92793 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16535286 0.89 MEN1 (0.40) —
SCHEMBL28271915 0.89 KDM4E (0.36) —
SCHEMBL16534729 0.88 EED (0.30) —
SCHEMBL16534745 0.86 MAP4K1 (0.33) —
SCHEMBL16535509 0.81 KDM5A (0.32) —
SCHEMBL16535079 0.77 KDM4E (0.32) —
SCHEMBL16534837 0.76 PDE4A (0.38) —
SCHEMBL16534876 0.75 EGLN2 (0.35) BRD4
SCHEMBL16535379 0.75 PDE10A (0.30) —
SCHEMBL16534881 0.74 CYP2C19 (0.45) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3041474-B1 ANTIPROLIFERATIVE COMPOUNDS GENENTECH INC (US) 2020-03-18 — — EP disclosed
US-9505767-B2 Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors GENENTECH, INC. (US) 2016-11-29 — — US disclosed
US-9505767-B2 Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors GENENTECH, INC. (US) 2016-11-29 — — US disclosed
US-9505767-B2 Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors GENENTECH, INC. (US) 2016-11-29 — — US disclosed
WO-2015035062-A1 ANTIPROLIFERATIVE COMPOUNDS GENENTECH, INC. (US) 2015-03-12 — — WO disclosed
US-20150065522-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. 2015-03-05 — — US disclosed
US-20150065522-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. 2015-03-05 — — US disclosed
US-20150065522-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. 2015-03-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150065522-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF KDM5A, KDM5B, KDM5C PARP1 651/4885PARP2 939/4885PARP6 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback